1. Home
  2. MDGL vs BIO Comparison

MDGL vs BIO Comparison

Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • BIO
  • Stock Information
  • Founded
  • MDGL 2011
  • BIO 1952
  • Country
  • MDGL United States
  • BIO United States
  • Employees
  • MDGL N/A
  • BIO N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • MDGL Health Care
  • BIO Industrials
  • Exchange
  • MDGL Nasdaq
  • BIO Nasdaq
  • Market Cap
  • MDGL 6.8B
  • BIO 6.7B
  • IPO Year
  • MDGL N/A
  • BIO N/A
  • Fundamental
  • Price
  • MDGL $290.96
  • BIO $248.63
  • Analyst Decision
  • MDGL Strong Buy
  • BIO Strong Buy
  • Analyst Count
  • MDGL 10
  • BIO 4
  • Target Price
  • MDGL $420.63
  • BIO $330.50
  • AVG Volume (30 Days)
  • MDGL 361.7K
  • BIO 323.3K
  • Earning Date
  • MDGL 05-01-2025
  • BIO 05-01-2025
  • Dividend Yield
  • MDGL N/A
  • BIO N/A
  • EPS Growth
  • MDGL N/A
  • BIO N/A
  • EPS
  • MDGL N/A
  • BIO N/A
  • Revenue
  • MDGL $317,383,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • MDGL $264.55
  • BIO $0.84
  • Revenue Next Year
  • MDGL $67.21
  • BIO $4.64
  • P/E Ratio
  • MDGL N/A
  • BIO N/A
  • Revenue Growth
  • MDGL N/A
  • BIO N/A
  • 52 Week Low
  • MDGL $200.08
  • BIO $215.38
  • 52 Week High
  • MDGL $377.46
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 40.85
  • BIO 52.73
  • Support Level
  • MDGL $280.00
  • BIO $231.75
  • Resistance Level
  • MDGL $307.54
  • BIO $257.66
  • Average True Range (ATR)
  • MDGL 15.97
  • BIO 10.39
  • MACD
  • MDGL -2.00
  • BIO 1.33
  • Stochastic Oscillator
  • MDGL 15.88
  • BIO 68.59

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: